mRNA vaccines (e.g., BCMA-mRNA lipid nanoparticle vaccines or personalized neoantigen platforms) could generate broad polyclonal CD8+/CD4+ responses against multiple tumor-associated antigens simultaneously, dramatically lowering escape probability compared with monovalent therapies. The gene discussed is CD8A; the disease is neoplasm.